Dr. Susan S Bratschi, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 633 Governor Carlos Camacho Rd., Ste. 210, Tamuning, GU 96913 Phone: 671-649-1001 Fax: 671-649-1002 |
Dr. Byungsoo Kim, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 472 Chalan San Antonio, Tamuning, GU 96913 Phone: 671-646-3880 Fax: 671-646-3887 |
News Archive
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.
Adults with severe heart failure see almost three times as many Medicare providers each year compared to a typical beneficiary, according to research presented at the American Heart Association's Scientific Sessions 2008.
Citing a review by Telegraph correspondent Rob Crilly criticizing the film Zero Dark Thirty "for getting its facts wrong about the CIA vaccination campaign that sought to confirm the DNA of Osama bin Laden's children," development blogger Tom Murphy writes in the Humanosphere blog, "Crilly's larger point is to say that the film gives further ammo to polio vaccine conspiracy theorists."
The Centers for Disease Control and Prevention is launching a new antibiotic tracking system allowing hospitals to monitor antibiotic use electronically, make better decisions about how to improve use, and compare themselves to other hospitals. Before now, CDC was only able to track antibiotic use in doctors' offices.
› Verified 8 days ago